Skip to main content

Atrophic vaginitis

Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Menopause article more useful, or one of our other health articles.

Synonyms: genitourinary syndrome of menopause, urogenital atrophy

Continue reading below

What is atrophic vaginitis?

Atrophic vaginitis is very common in postmenopausal women, due to the falling levels of oestrogen. The term genitourinary syndrome of menopause (GSM) is now usually used instead of vulvovaginal atrophy or atrophic vaginitis1 . It is defined as 'a group of chronic, progressive, hypo-oestrogenic conditions, including vulvovaginal atrophy, atrophic vaginitis, and bladder and urethral dysfunctions'2 .

During the reproductive years, the vaginal epithelium thickens under the influence of oestrogen and produces glycogen. As they die, the glycogen-rich cells provide food for Döderlein's bacilli, which in turn produce lactic acid, maintaining an acidic vaginal environment. After the menopause, oestrogen levels fall and this produces changes in the vagina:

  • The vaginal mucosa becomes thinner, drier, less elastic and more fragile. It may become inflamed.

  • The vaginal epithelium may become inflamed, contributing to urinary symptoms.

  • Changes in vaginal pH and vaginal flora may predispose to urinary tract infection (UTI) or vaginal infections.

  • Reduced oestrogen levels may affect periurethral tissues and contribute to pelvic laxity and stress incontinence.


Surveys have shown that 45% to 63% of postmenopausal women have experienced vulvovaginal symptoms, most commonly vaginal dryness. However, many women do not seek professional help or advice regarding their symptoms3 .

The following can lead to atrophic vaginitis occurring:

  • Natural menopause or oophorectomy.

  • Anti-oestrogenic treatments - eg, tamoxifen, aromatase inhibitors.

  • Radiotherapy or chemotherapy.

  • It can also occur postpartum or with breast-feeding, due to reduced oestrogen levels.

Continue reading below

Atrophic vaginitis symptoms4

It is important to initiate discussion regarding any vaginal dryness with postmenopausal women, as many women are very reluctant to talk about it or initiate conversation about it. Women are poorly aware that vulvovaginal atrophy is a chronic condition with a significant impact on sexual health and quality of life and that effective and safe treatments may be available5 .


  • There may be no symptoms.

  • Dryness of the vagina is the most common symptom, affecting up to 93% of women; this symptom is characterised as being moderate to severe in intensity in 68% of the cases6 .

  • There may be burning or itching of the vagina or vulva.

  • Dyspareunia.

  • Vaginal discharge (usually white or yellow).

  • Vaginal bleeding or postcoital bleeding.

  • Urinary symptoms - eg, increased frequency, nocturia, dysuria, recurrent UTI, stress incontinence or urgency.

  • Decreased arousal, desire and orgasm.


  • External genitalia may show reduced pubic hair, reduced turgor or elasticity, and a narrow introitus.

  • Be aware that vaginal examination may be uncomfortable or painful if the patient has atrophic vaginitis.

  • Vaginal examination may show:

    • Thin mucosa with diffuse erythema.

    • Occasional petechiae or ecchymoses.

    • Dryness.

    • Lack of vaginal folds.

    • Prolapse of urethra and/or vagina.

  • Atrophic vaginitis may be diagnosed by the practice nurse when a smear is being taken.


  • Investigations may not be necessary if the diagnosis is clear and there are no clinical features causing concern.

  • Investigation may be needed to exclude other problems:

    • Any postmenopausal bleeding requires investigation.

    • If there is discharge or bleeding, an infection screen may be relevant (for vaginal infections or endometritis).

    • Other causes of recurrent UTI.

    • Screen for diabetes may be considered (uncontrolled diabetes can contribute to symptoms).

  • Other possible investigations are:

    • Vaginal pH testing (using pH paper and sampling from the mid-vagina, not the posterior fornix). The result is more alkaline in atrophic vaginitis.

    • Vaginal cytology - can show lack of maturation of the vaginal epithelium, typical of atrophic vaginitis.

  • Assessment tools may be useful in evaluating severity of symptoms and their response to treatment7 .

Continue reading below

Differential diagnosis

  • Genital infections - eg, bacterial vaginosis, trichomonas, candidiasis, endometritis:

    • These may co-exist, as atrophic vaginitis predisposes the vagina to bacterial infection.

    • Trichomonas and bacterial vaginosis also give a more alkaline result on pH testing (pH>4.5).

  • Other causes of vaginal bleeding or postmenopausal bleeding.

  • Uncontrolled diabetes may cause vaginal or urinary symptoms.

  • Local irritation due to soap, panty liners, spermicides, condoms, biological washing powder and tight-fitting clothes.

  • Hot flushes mimic thyroid disease, malignancies, hypoglycaemia, carcinoid, and phaeochromocytoma.

Atrophic vaginitis treatment and management8

In most cases, it can be managed successfully. Treatments are often underused because of patient and clinician lack of knowledge of available treatments, embarrassment about initiating a discussion of symptoms and reluctance to initiate hormonal therapy.

A number of different treatments are available. These include vaginal lubricants and moisturisers, vaginal oestrogen and hormone replacement therapy (HRT).

The principles of management are:

  • Restoration of urogenital physiology.

  • Alleviation of symptoms.

Non-hormonal treatments

Personal lubricants and moisturisers can be effective at relieving discomfort and pain during sexual intercourse for women with mild to moderate vaginal dryness, particularly those who have a genuine contra-indication to oestrogen, or who choose not to use oestrogen9 . Regular sexual activity can be beneficial for many women10 .


  • These provide short-term relief.

  • They can improve dryness during intercourse.

  • There is no evidence that they have any long-term beneficial therapeutic effects.

  • Some are water based non-hormonal vaginal lubricants.

  • Others are silicone-based lubricants.


  • These are bio-adhesive so attach to mucin and epithelial cells on the vaginal wall and therefore retain water.

  • They can also lower vaginal pH.

  • Numerous preparations are available over the counter.

  • They are non-hormonal vaginal moisturisers.

  • Typical use might be one application (2.5 g) three times per week for an initial period of three months. It can be continued longer term if it is beneficial. It can be used more or less frequently, depending on the severity of the woman's dryness. It is safe to use daily.

  • These should be used regularly rather than during sexual intercourse.

  • NB: Vaseline® is not recommended. It can break down the latex in condoms or damage sex toys.

The efficacy of lubricants and moisturisers is generally lower than that with using topical oestrogens, although some experts believe that when they are applied on a regular basis then they have an efficacy comparable with that of local oestrogen therapy10 .

Laser treatment11
In 2021 the National Institute for Health and Care Excellence (NICE) issued guidance for the use of transvaginal laser therapy for urogenital atrophy . As there is inadequate evidence on long-term safety and efficacy, it recommends that this procedure should only be used in the context of research.

Prasterone is a synthetic DHEA equivalent that is approved for the treatment of moderate-to-severe dyspareunia. Prasterone is taken vaginally, once daily at bedtime, and has no restrictions on duration of use. It is associated with significant improvements in the severity of vaginal symptoms while serum levels of estradiol and testosterone remain within normal limits.

Ospemifene is a selective oestrogen receptor modulator used to treat moderate-to-severe dyspareunia and moderate-to-severe vaginal dryness. Ospemifene (60-mg oral dose) reduces the severity of dyspareunia and has beneficial effects for vaginal dryness and bone as well as anti-oestrogenic effects on breast tissue. The most common side-effect is hot flushes.

Hormonal treatments
Topical and systemic oestrogens are the most efficacious treatments for atrophic vaginitis.


  • Restores the vaginal pH.

  • Works by thickening and revascularising the vaginal epithelium, so improving lubrication.

  • Also helps to improve urinary symptoms.

  • Systemic HRT is not usually recommended as first-line treatment for those women with only vaginal symptoms and no menopausal symptoms.

  • Around 10-25% of women receiving HRT still have symptoms and so will require topical oestrogen in addition to HRT.

Topical treatments13
See also the separate HRT - Topical article.

  • There are various preparations available, including rings, vaginal tablets and creams. These are all equally effective for treating vaginal atrophy.

  • It is common to have more vaginal discharge with creams. This may be an advantageous side-effect in sexually active women.

  • Individual preference is important when deciding on which type of topical treatment to prescribe.

  • Topical HRT is sometimes used prior to prolapse repair surgery in postmenopausal women with evidence of epithelial atrophy.

  • Vaginal oestrogens can be really effective in patients with urinary urgency, frequency or nocturia, urinary incontinence and recurrent UTIs14 .

  • There is no evidence that topical oestrogen causes endometrial proliferation after long-term use5 .

  • Low-dose topical oestrogen does not therefore need to be given with systemic progestogens.

  • Long-term low-dose topical oestrogen is safe.

Most women will have relief from their symptoms after about three weeks of treatment. Maximal benefit usually occurs after 1-3 months but may take up to a year.

Women receiving hormonal treatment should all be advised to contact their doctor if they experience any vaginal bleeding.

If symptoms have not improved with hormonal treatment, then another underlying cause of the symptoms should be considered (eg, dermatitis, vulvodynia).


Vasomotor symptoms improve over 2-5 years but (rarely), may last to up to 20 years post-menopause. The duration varies with ethnicity - Asian women usually having a shorter duration and longer in African American women.

Hormonal treatment can reduce the frequency and severity of hot flushes by 75% and 87% respectively. It also improves the osteoporosis risk and subsequent risk of fracture. The genitourinary symptoms (such as dryness and itch) do not improve over time and return once the treatment is stopped.

Further reading and references

  • Paladine HL, Desai UA; Vaginitis: Diagnosis and Treatment. Am Fam Physician. 2018 Mar 1;97(5):321-329.
  • Nappi RE, Martini E, Cucinella L, et al; Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women. Front Endocrinol (Lausanne). 2019 Aug 21;10:561. doi: 10.3389/fendo.2019.00561. eCollection 2019.
  • Peters KJ; What Is Genitourinary Syndrome of Menopause and Why Should We Care? Perm J. 2021 May;25. doi: 10.7812/TPP/20.248.
  1. Portman DJ, Gass ML; Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014 Oct;21(10):1063-8. doi: 10.1097/GME.0000000000000329.
  2. Flores SA, Hall CA; Atrophic Vaginitis
  3. Nappi RE, Palacios S; Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014 Feb;17(1):3-9. doi: 10.3109/13697137.2013.871696.
  4. Angelou K, Grigoriadis T, Diakosavvas M, et al; The Genitourinary Syndrome of Menopause: An Overview of the Recent Data. Cureus. 2020 Apr 8;12(4):e7586. doi: 10.7759/cureus.7586.
  5. Kim HK, Kang SY, Chung YJ, et al; The Recent Review of the Genitourinary Syndrome of Menopause. J Menopausal Med. 2015 Aug;21(2):65-71. doi: 10.6118/jmm.2015.21.2.65. Epub 2015 Aug 28.
  6. Moral E, Delgado JL, Carmona F, et al; Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018 Apr;21(2):167-173. doi: 10.1080/13697137.2017.1421921. Epub 2018 Feb 7.
  7. Mension E, Alonso I, Tortajada M, et al; Genitourinary Syndrome of Menopause Assessment Tools. J Midlife Health. 2021 Apr-Jun;12(2):99-102. doi: 10.4103/jmh.jmh_93_21. Epub 2021 Jul 27.
  8. Da Silva AS, Baines G, Araklitis G, et al; Modern management of genitourinary syndrome of menopause. Fac Rev. 2021 Mar 3;10:25. doi: 10.12703/r/10-25. eCollection 2021.
  9. Edwards D, Panay N; Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2015 Dec 26:1-11.
  10. Sinha A, Ewies AA; Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric. 2013 Jun;16(3):305-12. doi: 10.3109/13697137.2012.756466. Epub 2013 Jan 8.
  11. Transvaginal laser therapy for urogenital atrophy; NICE Interventional procedures guidance, May 2021
  12. Kagan R, Kellogg-Spadt S, Parish SJ; Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause. Drugs Aging. 2019 Oct;36(10):897-908. doi: 10.1007/s40266-019-00700-w.
  13. Faubion SS, Sood R, Kapoor E; Genitourinary Syndrome of Menopause: Management Strategies for the Clinician. Mayo Clin Proc. 2017 Dec;92(12):1842-1849. doi: 10.1016/j.mayocp.2017.08.019.
  14. Rahn DD, Carberry C, Sanses TV, et al; Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014 Dec;124(6):1147-56. doi: 10.1097/AOG.0000000000000526.
  15. Koothirezhi R, Ranganathan S; Postmenopausal Syndrome

Article history

The information on this page is written and peer reviewed by qualified clinicians.

symptom checker

Feeling unwell?

Assess your symptoms online for free